Nicolas Cedric Boyer
15Patents
3h-index
62Co-inventors
59Inventor score
Filing activity: Jun 25, 2010 → Sep 27, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9353150B2 | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment | Chemistry; Metallurgy | 9 | Active |
| US10220099B2 | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | Chemistry; Metallurgy | 6 | Active |
| US11530244B2 | Cyclic polypeptides for PCSK9 inhibition | Human Necessities | 4 | Active |
| US10918735B2 | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | Chemistry; Metallurgy | 3 | Active |
| US9644004B2 | Peptide and peptidomimetic inhibitors | Human Necessities | 1 | Active |
| US9238676B2 | Peptide and peptidomimetic inhibitors | Human Necessities | 1 | Active |
| US10272132B2 | Peptide and peptidomimetic inhibitors | Human Necessities | 1 | Active |
| US8309341B2 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | Chemistry; Metallurgy | 0 | Active |
| US12365706B2 | Macrocyclic peptides as potent inhibitors of K-RAS G12D mutant | Chemistry; Metallurgy | 0 | Active |
| US11814444B2 | Cyclic polypeptides for PCSK9 inhibition | Human Necessities | 0 | Active |
| US9999650B2 | Peptide and peptidomimetic inhibitors | Human Necessities | 0 | Active |
| US11932705B2 | Cyclic polypeptides for PCSK9 inhibition | Human Necessities | 0 | Active |
| US12012468B2 | Cyclic polypeptides for PCSK9 inhibition | Human Necessities | 0 | Active |
| US11505575B2 | Cyclic polypeptides for PCSK9 inhibition | Human Necessities | 0 | Active |
| US11814445B2 | Cyclic polypeptides for PCSK9 inhibition | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.